SecBot SecBot
DEFA14A ·Filed Apr 28, 2026

CABA

Cabaletta Bio, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago SEC0001193125-26-183564
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for any activist campaigns or further filing details regarding the share increase. The doubling of authorized shares could lead to dilution if issued.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.86
T+0 close · Apr 28, 2026 · via day close
Latest settled
−4.90%
T+60 · $2.72
Vs SPY
−8.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $2.86entry
  2. T+1 · 7mo ago −2.80%α −2.79% · $2.78
  3. T+5 · 7mo ago +45.10%α +43.41% · $4.15
  4. T+20 · 6mo ago +33.92%α +28.46% · $3.83
  5. T+60 · 4mo ago −4.90%α −8.88% · $2.72

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio files additional proxy materials for its 2026 annual meeting. The board recommends voting FOR all proposals including election of two Class I directors, ratification of Ernst & Young as auditor, approval of amendments to the 2019 stock plan and charter to double authorized shares, say-on-pay, and adjournment. The most notable item is the proposed increase in authorized common stock from 300M to 600M, signaling potential future dilution.

Key Financial Metrics

Vote
director election
Meeting
2026-06-09
Seats Contested
2

Key Facts

  • Annual meeting scheduled for June 9, 2026
  • Stockholders of record as of April 20, 2026
  • Proposal to double authorized shares from 300M to 600M
  • Amendment to 2019 Stock Option and Incentive Plan
  • Board unanimously recommends FOR all six proposals

Financial Impact

Not specified

Risk Factors

  • Potential shareholder dilution if authorized shares are issued
  • No material financial data disclosed in this filing

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-183564
Document: 0001193125-26-183564-index-headers.html0001193125-26-183564
Document: 0001193125-26-183564-index.html0001193125-26-183564
Document: 0001193125-26-183564.txt0001193125-26-183564

Track record

29 reports on CABA

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026